Interstitial lung diseases (ILDs) represent a complex, heterogeneous group of pulmonary conditions, characterized by inflammation and fibrosis of the lung interstitium. This article aims to provide an in-depth overview of ILDs, focusing on their classification, pathogenesis, clinical manifestations, diagnosis, and management.
ILDs are broadly classified into two categories: idiopathic and secondary. Idiopathic interstitial pneumonias are the most common ILDs, with idiopathic pulmonary fibrosis (IPF) being the most prevalent. Secondary ILDs occur due to systemic diseases, environmental exposures, or drug toxicity.
The pathogenesis of ILDs is multifactorial and involves interplay between genetic predisposition, environmental factors, and immune dysregulation. This leads to alveolar epithelial injury, followed by abnormal wound healing, inflammation, and fibrosis.
Patients with ILDs typically present with progressive dyspnea and non-productive cough. Physical examination may reveal crackles and clubbing. High-resolution computed tomography (HRCT) is the gold standard for diagnosis, often showing reticular abnormalities, honeycombing, and ground-glass opacities. Pulmonary function tests show a restrictive pattern with reduced diffusion capacity.
Management of ILDs is primarily aimed at halting disease progression, alleviating symptoms, and improving quality of life. Therapeutic strategies include anti-inflammatory and anti-fibrotic drugs, lung transplantation in severe cases, and supportive care including oxygen therapy and pulmonary rehabilitation.
ILDs are a diverse group of lung disorders with shared pathogenic mechanisms and clinical manifestations. Understanding the classification, pathogenesis, clinical features, and management strategies is essential for healthcare professionals to ensure optimal patient care. Continued research is needed to further elucidate the pathogenesis and develop novel therapeutic strategies for these challenging diseases.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation